Category Archives: NMPA

NMPA Commissioner Huang Guo Inspects Tibetan Medicine Development in Xizang – Signals Push on Standards, Classical‑Formula Drug Conversion and Sustainable Sourcing

Inspection Milestone

Item	Detail
Delegation Head	Huang Guo – Party Secretary & Commissioner, NMPA
Locations	Lhasa and Shannan, Xizang Autonomous Region
Sites Visited	Pharmaceutical enterprises, medical institutions, grassroots market regulation departments, Tibetan medicinal‑material cultivation & breeding bases
Focus Areas	Tibetan medicine standard formulation/revision; new drug R&D; application of institutional preparations in medical facilities; grassroots drug regulation; production management of Tibetan medicinal materials
Participating Units	Heads of relevant NMPA departments and directly affiliated units
Stated Goal	Inherit, develop and utilize Tibetan medicine well – upholding both inheritance and innovation

Inspection Itinerary & Focus

Lhasa: The delegation visited pharmaceutical enterprises and medical institutions, examining in detail the formulation and revision of Tibetan medicine standards, new Tibetan drug R&D, and the clinical application of Tibetan medicine institutional preparations (hospital‑compounded formulations).
Shannan: The delegation inspected grassroots market regulation departments, pharmaceutical enterprises and Tibetan medicinal‑material cultivation and breeding bases, reviewing grassroots drug supervision, innovative drug development and production management of Tibetan medicinal materials.

Policy Directives Outlined

Standards Acceleration: Hasten the improvement of the Tibetan medicine standards system, leveraging the sector’s unique resource endowment and formulary experience.
Classical‑Formula Development: Intensify the development and utilization of ancient classical formulas, and promote the conversion of classical prescriptions and medical‑institution preparations into new drugs.
Three‑in‑One Evidence System: Deepen the application – in Tibetan new drug R&D – of the registration review evidence system that combines traditional Chinese medicine theory, human‑use experience and clinical trials, and strengthen communication and exchange across the entire R&D process.
Resource Protection & Sustainability: Strengthen the protection of Tibetan medicinal‑material resources, advance standardized (Good Agricultural Practice‑style) cultivation, ensure material quality and promote the sustainable development of Tibetan medicine.

Regulatory Context

Three‑Combined Evidence Pathway: The theory–human experience–clinical trial evidence framework was introduced nationally for traditional Chinese medicine registration, allowing human‑use experience to support drug applications – its explicit extension to Tibetan medicine lowers the evidentiary friction for ethnic‑medicine drug developers.
Institutional‑Preparation Pipeline: Hospital preparations with long clinical track records are a recognized seed pool for new drug conversion under China’s TCM reform agenda; Tibetan medicine institutions in Xizang hold sizable preparation portfolios.
Classical Formula Catalogs: Ancient classical formulas enjoy simplified registration pathways when developed per catalogue requirements, a mechanism the NMPA now seeks to activate for Tibetan formulary heritage.
Grassroots Supervision: Inspection of county‑level market regulation capacity signals attention to enforcement infrastructure for cultivation, processing and distribution quality of Tibetan medicinal materials.

Market Impact & Outlook

Ethnic‑Medicine Modernization: The inspection places Tibetan medicine high‑quality development squarely on the NMPA’s national agenda, likely catalyzing standards issuance, registration guidance and pilot programs for Xizang‑based enterprises.
R&D Opportunity Window: Developers able to package classical formulas or institutional preparations into registrable new drugs – supported by the three‑combined evidence system – gain a differentiated, policy‑endorsed pathway.
Supply‑Chain Upgrading: Emphasis on resource protection and standardized cultivation points to investment in GAP‑compliant cultivation and breeding bases, with implications for material quality, traceability and long‑term supply security.
Timeline & Measures: Specific policy instruments, funding and deadlines emerging from the inspection were not disclosed in the readout.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding Tibetan medicine standard‑setting, classical‑formula drug conversion, registration evidence‑system application and cultivation standardization following the NMPA inspection in Xizang. Actual outcomes may differ due to risks including policy formulation timelines, registration review requirements, resource and supply‑chain conditions, and enterprise execution capabilities.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/yaowen/ypjgyw/ypyw/20260911195710154.html

China’s CDE Opens Public Consultation on Technical Guidelines for Anti‑Tuberculosis Drug Clinical Trials – One‑Month Comment Window on Draft Framework

Regulatory Milestone

Item	Detail
Agency	Center for Drug Evaluation (CDE), NMPA (China)
Action Type	Public consultation on draft technical guideline
Document	Technical Guidelines for Clinical Trials of Anti‑Tuberculosis Drugs (Draft for Comments)
Purpose	Address the R&D needs of innovative anti‑TB drugs and standardize clinical trial design and conduct
Issue Date	9 September 2026
Comment Period	One month from publication (closing circa 9 October 2026)
Feedback Channels	zhaiy@cde.org.cn; chengjw@cde.org.cn
Next Steps	Revision and finalization of the guideline following review of public comments – detailed timeline Not disclosed

Guideline Scope & Policy Context

Objective: The draft was prepared by the CDE specifically “to meet the development needs of innovative anti‑pulmonary tuberculosis drugs,” signaling dedicated regulatory guidance for a therapeutic area historically underserved by tailored trial standards.
Consultation Approach: The CDE explicitly invites stakeholders across industry, academia, and the public to submit recommendations, with feedback to be incorporated in subsequent refinement of the guideline.
Specific Technical Provisions: Detailed trial design requirements, endpoint definitions, and population criteria in the draft – Not disclosed in the announcement itself; full text available via the CDE consultation posting.
Regulatory Pattern: The move extends China’s steady build‑out of disease‑specific technical guideline systems, giving sponsors earlier clarity on evidentiary expectations for anti‑TB clinical programs.

Clinical & Disease Context

Disease Burden: Tuberculosis remains among the world’s leading infectious‑disease causes of mortality, with China carrying one of the largest national TB burdens globally – underpinning sustained demand for innovative anti‑TB therapeutics.
Unmet Need: Drug‑resistant TB, lengthy treatment durations, and tolerability limitations of existing regimens continue to drive R&D toward new mechanisms and shorter, more effective combinations.
Trial Complexity: Anti‑TB trials involve distinct challenges – bacteriological endpoints, long follow‑up, relapse assessment, and combination‑regimen design – making standardized technical guidance a meaningful de‑risking tool for sponsors.

Market Impact & Outlook

Sponsor Implications: For domestic and multinational developers of anti‑TB candidates, finalized guidelines should reduce regulatory uncertainty in trial design and support more predictable review pathways in China.
Innovation Signal: Disease‑specific guidance reinforces the CDE’s broader policy direction of channeling structured support toward high‑unmet‑need infectious disease innovation.
Industry Participation: With a defined one‑month window, affected companies are expected to mobilize clinical, regulatory, and legal teams to shape provisions that will govern future TB trial submissions.
Final Guideline Timing: Publication date of the finalized version – Not disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the finalization of the Technical Guidelines for Clinical Trials of Anti‑Tuberculosis Drugs, associated regulatory timelines, and the implications for clinical development programs. The draft remains subject to change based on public feedback; actual outcomes may differ due to regulatory, technical, and policy considerations.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/ed1b82a54ba2a669d8f1af21a100ce17

China’s CDE Taps Bona Biomedical’s CD19 Allogeneic CAR-T for Rare Disease Pilot – Novel Cell Therapy Aimed at Relapsed/Refractory Systemic Sclerosis

Regulatory Milestone

Item	Detail
Agency	Center for Drug Evaluation (CDE), NMPA (China)
Action Type	Public notice of proposed inclusion in the Rare Disease Innovative Drug R&D Incentive Pilot (“Care Program – Extension”)
Product	CD19‑targeted gene‑modified allogeneic CAR‑T injection
Applicant	Shanghai Bona Biomedical Co., Ltd.
Planned Indication	Relapsed/refractory systemic sclerosis (SSc)
Notice Date	9 September 2026
Comment Deadline	16 September 2026 (objections via zhaona@cde.org.cn)
Next Steps	Formal pilot inclusion after the notice period; subsequent review under pilot incentives – detailed timelines Not disclosed

Drug Profile & Mechanism of Action

Modality: Allogeneic (“off‑the‑shelf”) CAR‑T cell therapy – manufactured from healthy donor T cells rather than harvested from each patient, in contrast to autologous CAR‑T products currently on the market.
Target: CD19, a surface antigen expressed across the B‑cell lineage; depleting autoreactive B cells has emerged as a mechanistic strategy in B‑cell–driven autoimmune diseases, including systemic sclerosis.
Innovation: A gene‑modified allogeneic design intended to bypass the manufacturing lead time and patient T‑cell quality constraints of autologous therapy while enabling scalable, repeatable supply.
Clinical Stage / Data: Not disclosed in the CDE announcement.

Policy Context – “Care Program – Extension” Pilot

Program: Established under the CDE’s application guidelines for encouraging innovative drug R&D in rare diseases, the pilot is designed to channel regulatory support and review incentives toward candidates addressing conditions of high unmet need.
Unmet Need: Systemic sclerosis is a rare, progressive autoimmune fibrotic disorder; patients with relapsed/refractory disease have limited therapeutic options, making SSc a priority target for innovative modalities.
Mechanistic Rationale: CD19‑directed B‑cell depletion represents a departure from conventional immunosuppression, aiming at deep immune reset rather than symptom control – a hypothesis now moving into formally incentivized development in China.
Incentive Details: Specific benefits conferred by pilot inclusion – Not disclosed in this notice.

Market Impact & Outlook

China Cell Therapy Landscape: Should the program advance, an allogeneic CAR‑T for autoimmune disease would address key accessibility bottlenecks of autologous products – vein‑to‑vein time, manufacturing failures, and capacity limits – in the world’s second‑largant pharmaceutical market.
Rare Disease Strategy: The notice reinforces the CDE’s continued push to build a dedicated incentive pathway for rare disease innovation, signaling earlier regulatory engagement for qualifying programs.
Competitive Edge: Bona’s off‑the‑shelf CD19 approach positions the company in the fast‑expanding autoimmune CAR‑T race, where most competitors remain focused on autologous formats or hematologic oncology.
Pipeline Positioning: Proposed inclusion elevates the visibility of Shanghai Bona Biomedical’s allogeneic cell therapy platform ahead of formal pilot confirmation; commercialization plans and partnerships – Not disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the proposed pilot inclusion, regulatory timelines, clinical development, and commercial expectations for Bona Biomedical’s CD19‑targeted allogeneic CAR‑T injection. The proposal remains subject to the public consultation period and final CDE determination; actual results may differ due to regulatory, clinical, manufacturing, and competitive risks.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/f56f5a13f9edb44cbcb4226e2a496efd